The author scrutinizes the results of a new pilot study that finds the Fisher Wallace Stimulator® effective in treating bipolar depression.
Simply telling patients “we don’t know how ECT works” neglects our abundant knowledge of what this treatment does. The authors review biological actions of ECT and discuss future directions for research.
This review covers recent advances in ECT technique, post-ECT management, and theories of mechanism of action. It will focus on the use of ECT in depression, the most common indication for ECT in clinical practice.
What role might electroconvulsive therapy play for short-term treatment of agitation and aggression in patients with dementia?
Some recent breakthroughs, using newly developed neuroscience investigational tools, suggest that if research resources are available, we could soon make substantial advances in understanding the mechanism of action of ECT.
We have medications that can affect serotonin, norepinephrine, and—to a lesser extent—dopamine. Many other neurotransmitters are involved with mood disorders, but we have no medications yet to target them. Neurostimulation offers a non-systemic somatic approach to depression, often with an improved side effect profile. More in this Q&A.
Earn CME Credits for reading Psychiatric Times articles. Click here to go to our free online CME activities.